{"doi":"10.1371/journal.pone.0139828","title":"Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G","abstract":null,"journal":"PLOS ONE","year":2015,"id":630970,"datarank":0.42498200160843247,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.0,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1236982,"name":"David Falck","orcid":"0000-0003-3908-2376","position":1,"is_corresponding":false},{"id":1634917,"name":"Tom C. M. Santbergen","orcid":null,"position":2,"is_corresponding":false},{"id":849856,"name":"Ruth Huizinga","orcid":"0000-0002-9563-4860","position":3,"is_corresponding":false},{"id":53131,"name":"Manfred Wuhrer","orcid":"0000-0002-0814-4995","position":4,"is_corresponding":false},{"id":288774,"name":"Bart C. Jacobs","orcid":"0000-0002-8985-2458","position":5,"is_corresponding":false},{"id":1634916,"name":"Willem Jan R. Fokkink","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G","abstract":"Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features (galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26457892","pmcid":"PMC4601728","openalex_id":"https://openalex.org/W2258228646","authors":[],"funders":[{"funder_name":"ZonMw","grant_id":"93511033","title":null},{"funder_name":"European Commission","grant_id":"278535","title":"Methods for high-throughput (HTP) analysis of protein glycosylation"}],"total_grants":2,"fwci":1.2244,"citation_percentile":0.79632628,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2017,"count":2},{"year":2018,"count":2},{"year":2019,"count":1},{"year":2020,"count":4},{"year":2021,"count":2},{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0139828&type=printable","host_type":"journal"},{"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0139828&type=printable","host_type":"publisher"},{"url":"http://dx.plos.org/10.1371/journal.pone.0139828","host_type":"publisher"},{"url":"https://doi.org/10.1371/journal.pone.0139828","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26457892","host_type":"repository"},{"url":"https://research.vumc.nl/en/publications/d6d2a360-c4aa-466f-8a36-a770f46b6c0a","host_type":"repository"},{"url":"https://pure.eur.nl/en/publications/a9708791-ce0d-464b-8bd2-f0a066604c0d","host_type":"repository"},{"url":"https://research.vu.nl/en/publications/4171ea9b-fb5b-4124-8eaf-39e29209cfa1","host_type":"repository"},{"url":"https://pure.amsterdamumc.nl/en/publications/d792e6d0-bb8f-4256-8573-746347260579","host_type":"repository"},{"url":"http://hdl.handle.net/1765/89207","host_type":"repository"},{"url":"http://hdl.handle.net/1887/101104","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4601728","host_type":"repository"},{"url":"https://figshare.com/articles/dataset/Comparison_of_Fc_N_Glycosylation_of_Pharmaceutical_Products_of_Intravenous_Immunoglobulin_G/1572731","host_type":"repository"},{"url":"http://repub.eur.nl/pub/89207","host_type":"repository"},{"url":"https://hdl.handle.net/1871.1/4171ea9b-fb5b-4124-8eaf-39e29209cfa1","host_type":"repository"},{"url":"https://pure.amsterdamumc.nl/ws/files/173157682/Comparison-of-fc-n-glycosylation-of-pharmaceutical-products-of-intravenous-immunoglobulin-g.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4601728","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4601728?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1371/journal.pone.0139828","host_type":""},{"url":"https://doaj.org/article/ae505205b0db44d2b41beec27cd3fcc4","host_type":""},{"url":"https://dx.doi.org/10.1371/journal.pone.0139828","host_type":""},{"url":"https://hdl.handle.net/1887/101104","host_type":""}],"fields_of_study":["Monoclonal and Polyclonal Antibodies Research","Glycosylation and Glycoproteins Research","Complement system in diseases","0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":["Female","Glycosylation","Humans","Immunoglobulin G","Immunoglobulin Fc Fragments","Male","Immunoglobulins, Intravenous"],"keywords":["Glycosylation","Fucosylation","Antibody","Chemistry","Immunoglobulin G","N-linked glycosylation","Immunoglobulin Fc Fragments","Fragment crystallizable region","Immunology","Biochemistry","Glycoprotein","Glycan","Medicine","Male","EMC MM-02-72-02","Science","Q","R","Immunoglobulins, Intravenous","EMC MM-04-44-02","SDG 3 - Good Health and Well-being","Humans","Female","Research Article"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":8,"sdg_label":"8. Economic growth"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T22:32:32.389001Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}